Accessibility Menu
hVIVO Plc logo

hVIVO Plc(LSE) HVO

Current Price£0.07
Market Cap£46.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+16%
5 Year-73%
1 Year-31%
1 Month-9%
hVIVO Plc last closing stock price
MetricPriceDate
Last closeGBX 6.702026-07-23
hVIVO Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.19%GBX 6.852026-07-16
1 month-8.84%GBX 7.352026-06-23
3 month-13.55%GBX 7.752026-04-24
Year to date+6.35%GBX 6.302025-12-31
1 year-31.28%GBX 9.752025-07-23
3 year-56.35%GBX 15.352023-07-24
5 year-73.2%GBX 25.002021-07-23
Since inception+16.22%GBX 0.062019-07-01

hVIVO Plc Financials at a Glance

Market Cap

£46.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£110.75M

Net Income (TTM)

£4.66M

EPS (TTM)

-£0.01

P/E Ratio

-7.76

Dividend

£0.00

Beta (Volatility)

-0.07 (Low)

Price

£0.07

Volume

2,594,930

Open

£0.06

Previous Close

£0.07

Daily Range

£0.06 - £0.07

52-Week Range

£0.04 - £0.12

Estimated Earnings Date

Sep 15, 2026

HVO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About hVIVO Plc

hVIVO plc operates as a premier full-service Contract Research Organisation (CRO) specializing in early-phase clinical development. The company is recognized globally as a leader in human challenge trials, providing comprehensive clinical development services to a diverse client base, including major biopharmaceutical companies.

Products and Services
  • Human challenge trials for infectious and respiratory diseases
  • Virology and immunology laboratory services through hLAB
  • Early-phase clinical trial expertise via its German subsidiary, CRS
Growth Outlook
  • Strong demand for human challenge trials is expected to drive revenue growth
  • Expansion of laboratory services enhances competitive positioning
  • Strategic partnerships with leading biopharmaceutical companies support future growth
Financial Highlights
  • Recent quarterly revenue of £22.58 million reflects a solid client base
  • Trailing twelve months (TTM) revenue of £92.5 million indicates strong operational performance
  • Net income for the latest quarter was £-5.88 million, showing investment in growth
hVIVO plc is positioned in the biotechnology sector, focusing on innovative clinical research methodologies. The company’s unique capabilities in conducting human challenge trials provide a competitive edge, particularly in the context of rising global health challenges. The recent financial performance indicates a commitment to growth, despite facing operational losses, which are often typical in the early phases of clinical development. The strategic focus on expanding laboratory services and forming partnerships with major biopharmaceutical firms is likely to enhance revenue streams and market presence. Investors may find hVIVO plc an intriguing opportunity within the healthcare sector, given its specialized offerings and growth potential.
AI Generated • Jul 12, 2026

Industry

Life Sciences Tools and Services

CEO

Yamin Mohammed Khan

Headquarters

London, GL E1 1EQ, GB

HVO Financials

Key Financial Metrics (TTM)

Gross Margin

-6.07%

Operating Margin

-13.13%

Net Income Margin

-12.48%

Return on Equity

-14.65%

Return on Capital

-0.66%

Return on Assets

-8.35%

Earnings Yield

-12.89%

Dividend Yield

0.00%

Payout Ratio

-22.89%

Stock Overview

Market Cap

£46.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

688.40M

Volume

2.59M

Avg. Volume

1.96M

Financials (TTM)

Gross Profit

£59.81M

Operating Income

£6.55M

EBITDA

£17.59M

Operating Cash Flow

-£3.76M

Capital Expenditure

-£3.86M

Free Cash Flow

-£7.62M

Cash & ST Invst.

£14.30M

Total Debt

£14.79M

hVIVO Plc Performance Analysis

hVIVO Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 48,477,00031.5%
20232023-12-31GBP 56,043,00015.6%
20242024-12-31GBP 62,725,00011.9%
20252025-12-31GBP 46,773,000-25.4%
hVIVO Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3023.9%
Q42024-12-31-31.4%
Q22025-06-30-0.3%
Q42025-12-31-11.3%
hVIVO Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.001100.0%
20232023-12-31GBP 0.02N/A
20242024-12-31GBP 0.02-34.0%
20252025-12-31GBP -0.01N/A
hVIVO Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-56.8%
Q42024-12-313.9%
Q22025-06-30-102.5%
Q42025-12-31-4200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£22.58M

-24.8%

Gross Profit

-£5.93M

-175.8%

Gross Margin

-26.28%

N/A

Market Cap

£46.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£123.58K

N/A

Employees

376

N/A

Net Income

-£5.88M

-148.3%

EBITDA

-£3.23M

-147.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£14.30M

-61.3%

Total Debt

£14.79M

+18.0%

Accounts Receivable

£12.50M

-5.3%

Inventory

£691.00K

+62.2%

Long Term Debt

£12.30M

+1.1%

Short Term Debt

£2.49M

+578.2%

Return on Assets

-8.35%

N/A

Return on Invested Capital

-11.66%

N/A

Free Cash Flow

-£7.39M

-227.8%

Operating Cash Flow

-£6.57M

-162.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HEMO.LHemogenyx Pharmaceuticals Plc
£6.76-10.99%
POLB.LPoolbeg Pharma PLC
£0.06+0.82%
KOO.LKooth plc
£1.57-0.63%
SBTX.LSkinBioTherapeutics Plc
£0.12+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
AALAmerican Airlines Group
$13.56-0.08%
TAT&T
$22.96-0.00%
ONDSOndas
$7.93-0.01%

Questions About HVO

What is the current price of hVIVO Plc?

hVIVO Plc is trading at £0.07 per share.

What is the 52-week range for hVIVO Plc?

Over the past 52 weeks, hVIVO Plc has traded between £0.04 and £0.12.

How much debt does hVIVO Plc have?

As of the most recent reporting period, hVIVO Plc reported total debt of £14.79M.

How much cash does hVIVO Plc have on hand?

hVIVO Plc reported £14.30M in cash and cash equivalents in its most recent financial results.

What is hVIVO Plc’s dividend yield?

hVIVO Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.